GLP-1 clinical trials in Illinois: 28 recruiting now

28 GLP-1 clinical trials are recruiting at 40 sites in 10 cities across Illinois. Every site below is listed with its city and, where the sponsor publishes one, the number to call.

Every study recruiting in Illinois

1. A Phase 4, Prospective, Open-Label, Single-Arm Study to Assess the Effectiveness of Tirzepatide After Initiation of Ixekizumab

   Phase 4. Run by Eli Lilly and Company. Registry number NCT06864026.

   A study testing whether a GLP-1 and GIP medicine from Lilly, tirzepatide, can help people ease psoriatic arthritis.

   Who can join. Adults 18+, have psoriatic arthritis, BMI 27+.

   4 sites in Illinois

   • Great Lakes Clinical Trials - Ravenswood, Chicago. 7732753500
   • Greater Chicago Specialty Physicians, Schaumburg. 8475992492
   • Arnold Arthritis & Rheumatology, Skokie
   • Willow Rheumatology and Wellness PLLC, Willowbrook. 4349628466

2. PREvention of CardIovascular and DiabEtic kidNey Disease in Type 2 Diabetes

   Phase 4. Run by Brigham and Women's Hospital. Registry number NCT05390892.

   A study testing whether a GLP-1 medicine, semaglutide, can help people lower blood sugar.

   Who can join. Adults 40 to 80, have type 2 diabetes.

   2 sites in Illinois

   • University of Illinois Chicago, Chicago. 773-505-0169
   • Rush University Medical Center, Hinsdale. 630-724-1792

3. A Clinical Study to Compare Efficacy and Safety of Two Different Doses of CagriSema and Semaglutide in Participants With Obesity

   Phase 3. Run by Novo Nordisk A/S. Registry number NCT07564414.

   A study testing whether a study medicine from Novo Nordisk, cagrisema, can help people with type 2 diabetes lose weight.

   Who can join. Adults 18+, have obesity, BMI 35+.

   5 sites in Illinois

   • Cedar-Crosse Research Center, Chicago
   • Macoupin Fam Practice Ctr, LLP, Gillespie
   • Clinical Investigation Spec Gurnee, Gurnee
   • Endeavor Health, Skokie
   • Evanston Premier Hlthcr Res, Skokie

4. A Platform Trial for Pediatric Participants With Obesity or Overweight (LY900040)

   Phase 3. Run by Eli Lilly and Company. Registry number NCT06672549.

   A study testing whether a GLP-1 medicine from Lilly, orforglipron, can help people lose weight.

   Who can join. Children and teens 6 to 17, have obesity.

   2 sites in Illinois

   • Ann and Robert Lurie Children's Hospital of Chicago, Chicago. 312-503-1499
   • University of Illinois at Chicago, Chicago

5. Efficacy and Safety of Ribupatide Administered Once Weekly Compared With Semaglutide and Placebo in Participants Living

   Phase 3. Run by Kailera. Registry number NCT07284979.

   A study testing whether an investigational medicine from Kailera, KAI-9531, can help people lose weight.

   Who can join. Adults 18+, have obesity, BMI 35+.

   2 sites in Illinois

   • Kailera Clinical Site, Chicago
   • Kailera Clinical Site, Skokie

6. A Study of Tirzepatide in Adolescents With Obesity and Weight-Related Comorbidities (SURMOUNT-ADOLESCENTS-2)

   Phase 3. Run by Eli Lilly and Company. Registry number NCT06439277.

   A study testing whether a GLP-1 and GIP medicine from Lilly, tirzepatide, can help people lose weight.

   Who can join. Children and teens 12 to 17, have obesity.

   1 site in Illinois

   • Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago

7. Semaglutide for Metabolic Intervention and Adipose Loss to Treat Atrial Fibrillation

   Phase 3. Run by University of Chicago. Registry number NCT06499857.

   A study testing whether a GLP-1 medicine, semaglutide, can help people with atrial fibrillation lose weight.

   Who can join. Adults 18 to 75, have obesity or are overweight, BMI 30+.

   1 site in Illinois

   • University of Chicago, Chicago. 773-702-3275

8. A Study of Orforglipron (LY3502970) in Adolescent Participants With Obesity, or Overweight With Related Comorbidities

   Phase 3. Run by Eli Lilly and Company. Registry number NCT06672939.

   A study testing whether a GLP-1 medicine from Lilly, orforglipron, can help people lose weight.

   Who can join. Children and teens 12 to 17, have obesity.

   1 site in Illinois

   • Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago

9. Mirikizumab Administered at the Same Time as Tirzepatide in Adult Participants With Moderately to Severely Active Ulcerative

   Phase 3. Run by Eli Lilly and Company. Registry number NCT06937086.

   A study testing whether a GLP-1 and GIP medicine from Lilly, tirzepatide, can help people with ulcerative colitis calm gut inflammation.

   Who can join. Adults 18 to 70, have ulcerative colitis, BMI 27+.

   1 site in Illinois

   • Rush University Medical Center, Chicago

10. Mirikizumab and Tirzepatide Administered in Adult Participants With Moderately to Severely Active Crohn's Disease and Obesity

    Phase 3. Run by Eli Lilly and Company. Registry number NCT06937099.

    A study testing whether a GLP-1 and GIP medicine from Lilly, tirzepatide, can help people with Crohn's disease calm gut inflammation.

    Who can join. Adults 18 to 70, have Crohn's disease, BMI 27+.

    1 site in Illinois

    • Rush University Medical Center, Chicago

11. A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and Osteoarthritis (OA) of the Knee

    Phase 3. Run by Eli Lilly and Company. Registry number NCT07153471.

    A study testing whether a GLP-1 medicine from Lilly, orforglipron, can help people ease joint pain.

    Who can join. Adults 18+, have osteoarthritis (joint pain), BMI 27+.

    1 site in Illinois

    • Northwestern University, Chicago. 312-503-2315

12. A Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes)

    Phase 3. Run by Eli Lilly and Company. Registry number NCT07165028.

    A study testing whether a GLP-1, GIP and glucagon medicine from Lilly, retatrutide, can help people reduce liver fat.

    Who can join. Adults 18+, have fatty liver disease (MASLD), BMI 25+.

    1 site in Illinois

    • University of Chicago Medical Center, Chicago

13. Cessation or Reduction of Alcohol Consumption in Veterans: A Randomized Controlled Trial for Alcohol Use Disorder (CRAVE)

    Phase 3. Run by VA Office of Research and Development. Registry number NCT07218354.

    A study testing whether a GLP-1 medicine, semaglutide, can help people with alcohol use disorder drink less.

    Who can join. Adults 18 to 80, have alcohol use disorder, BMI 21+.

    1 site in Illinois

    • Edward Hines Jr. VA Hospital, Hines, IL, Hines. 708-202-8387

14. A Phase 3, Open-label Trial to Evaluate the Efficacy, Safety and Tolerability of Switching From the Glucagon-like Peptide-1

    Phase 3. Run by Amgen. Registry number NCT07575399.

    A study testing whether a study medicine from Amgen, Maridebart Cafraglutide, can help people lose weight.

    Who can join. Adults 18+, have obesity or are overweight, BMI 25+.

    1 site in Illinois

    • Endeavor Health, Skokie

15. A Randomized, Open-label, Parallel-group Phase III Study to Evaluate the Efficacy, Safety, and Tolerability of Elecoglipron

    Phase 3. Run by AstraZeneca. Registry number NCT07662213.

    A study testing whether a GLP-1 medicine, semaglutide, can help people with type 2 diabetes lower blood sugar.

    Who can join. Adults 18+, have type 2 diabetes, BMI 23+.

    1 site in Illinois

    • Research Site, Melrose Park

16. A Study to Test Whether Survodutide Helps People With Type 2 Diabetes Control Their Blood Sugar

    Phase 3. Run by Boehringer Ingelheim. Registry number NCT07754461.

    A study testing whether a GLP-1 and glucagon medicine from Boehringer Ingelheim, survodutide, can help people with type 2 diabetes lower blood sugar.

    Who can join. Adults 18+, have type 2 diabetes, BMI 23+.

    1 site in Illinois

    • Evanston Premier Healthcare Research LLC, Skokie. 833-602-2368

17. A Master Protocol Study (LY900038) of Multiple Intervention-Specific-Appendices (ISAs) in Adult Participants With Obesity

    Phase 2. Run by Eli Lilly and Company. Registry number NCT06143956.

    A study testing whether an investigational medicine from Lilly, LY3305677, can help people lose weight.

    Who can join. Adults 18 to 75, have obesity, BMI 27+.

    2 sites in Illinois

    • Great Lakes Clinical Trials - Ravenswood, Chicago
    • NorthShore University Health System, Skokie

18. A Research Study Comparing Different Ways of Increasing the Dose of NNC0662-0419 in Participants With Obesity

    Phase 2. Run by Novo Nordisk A/S. Registry number NCT07639021.

    A study testing whether an investigational medicine from Novo Nordisk, NNC0662-0419, can help people lose weight.

    Who can join. Adults 18+, have obesity, BMI 30+.

    2 sites in Illinois

    • Cedar-Crosse Research Center, Chicago
    • Great Lakes Clinical Trials, Chicago

19. Evaluation of Tirzepatide as an Adjunct to Buprenorphine for the Treatment of Opioid Use Disorder

    Phase 2. Run by T. John Winhusen, PhD. Registry number NCT06651177.

    A study testing whether a GLP-1 and GIP medicine, tirzepatide, can help people with opioid use disorder cut down on opioids.

    Who can join. Adults 18+, have opioid use disorder, BMI 23+.

    1 site in Illinois

    • Ruth M. Rothstein CORE Center, Chicago. 312-572-4753

20. A Research Study Comparing How Well Different Doses of the Medicine NNC0519-0130 Can Reduce Kidney Damage in People Living

    Phase 2. Run by Novo Nordisk A/S. Registry number NCT06717698.

    A study testing whether an investigational medicine from Novo Nordisk, NNC0519-0130, can help people with chronic kidney disease protect their kidneys.

    Who can join. Adults 18+, have chronic kidney disease, BMI 27+.

    1 site in Illinois

    • Endeavor Health, Skokie

Source: ClinicalTrials.gov, the federal registry, read September 4, 2026. Open a study's registry record before you call: it can close to new participants at any time. GLP Chart does not enroll anyone, is not paid for clinical-trial referrals and has no relationship with any sponsor or site on this page.

John Samaras, Founder and EditorI started GLP Chart after overpaying for a GLP-1 myself. Based in Austin, Texas.
About this siteLinkedInContact